Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
Neoadjuvant tislelizumab combined with chemotherapy demonstrated promising efficacy with encouraging pathological responses and survival outcomes in locally advanced ESCC, supporting clinical application.
Authors
- Hongtao Duan (ORCID: https://orcid.org/0000-0002-1985-2292)
- Hao Yin (ORCID: https://orcid.org/0000-0003-0258-1403)
- Yihua Sun (ORCID: https://orcid.org/0000-0001-8027-2927)
- Hong Fan (ORCID: https://orcid.org/0000-0003-2826-5564)
- Fei Liang (ORCID: https://orcid.org/0000-0002-4184-7844)
- Xuqiang Liao
- Li Gao (ORCID: https://orcid.org/0000-0003-2927-1827)
- Xiaolong Yan (ORCID: https://orcid.org/0000-0003-2419-9707)
- Xinyu Yang (ORCID: https://orcid.org/0000-0001-9433-667X)
- Guangyu Yao (ORCID: https://orcid.org/0000-0001-7389-0401)
- Jie Wang (ORCID: https://orcid.org/0000-0002-7491-7001)
- Yujie Chen (ORCID: https://orcid.org/0000-0002-3057-3956)
- Peiyuan Wang
- Lijie Tan (ORCID: https://orcid.org/0009-0006-3137-199X)
Institutions
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Zhongshan Hospital (CN)
- Hainan General Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- Tang Du Hospital (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1007/s00262-025-04240-8
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00